p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases.

[1]  S. Syrjänen,et al.  p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.

[2]  K. Weber,et al.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. , 1993, The American journal of pathology.

[3]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[4]  I. Ellis,et al.  p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.

[5]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[6]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[7]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[8]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[9]  J. Bartek,et al.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. , 1992, Journal of cell science.

[10]  A. Harris,et al.  Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. , 1991, Oncogene.

[11]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[12]  D. Lane,et al.  Expression of p53 protein in infiltrating and in‐situ breast carcinomas , 1991, The Journal of pathology.

[13]  S. Hirohashi,et al.  Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer , 1991, Japanese journal of cancer research : Gann.

[14]  B. Angus,et al.  p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study , 1991, The Journal of pathology.

[15]  G. Striker,et al.  Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. , 1990, The American journal of pathology.

[16]  O. Petersen,et al.  Regulation of vimentin expression in cultured human mammary epithelial cells. , 1990, Differentiation; research in biological diversity.

[17]  K. Weber,et al.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. , 1990, The American journal of pathology.

[18]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[19]  A S Leong,et al.  Vimentin—a new prognostic parameter in breast carcinoma? , 1989, The Journal of pathology.

[20]  A. Leong,et al.  Co‐expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium , 1989, The Journal of pathology.

[21]  K. Zedeler,et al.  Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action. , 1988, British Journal of Cancer.

[22]  F. Rilke,et al.  Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. , 1988, British Journal of Cancer.

[23]  Mark R. Segal,et al.  Regression Trees for Censored Data , 1988 .

[24]  J. Gerdes,et al.  Growth Fraction as Determined in Cytologic Specimens of Breast Carcinomas: A Study with the Monoclonal Antibody Ki-67 , 1988 .

[25]  U. Helmchen,et al.  Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. , 1987, The American journal of pathology.

[26]  N. Azumi,et al.  The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. , 1987, American journal of clinical pathology.

[27]  G M Clark,et al.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Kaczmarek,et al.  Coding sequence and growth regulation of the human vimentin gene , 1986, Molecular and cellular biology.

[29]  W. Drobyski,et al.  Estrogen receptors and the pattern of relapse in breast cancer. , 1984, Archives of internal medicine.

[30]  K. Weber,et al.  Monoclonal antibodies specific for vimentin. , 1984, European journal of cell biology.

[31]  N. Connell,et al.  Regulation of the cytoskeleton in mesothelial cells: Reversible loss of keratin and increase in vimentin during rapid growth in culture , 1983, Cell.

[32]  R. Blamey,et al.  Oestrogen-receptor status and sites of metastasis in breast cancer. , 1981, British Journal of Cancer.

[33]  R. Rubens,et al.  Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. , 1981, European journal of cancer.

[34]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[35]  H. Potter,et al.  Estrogen Receptor and Natural Course of Breast Cancer , 1976, Annals of surgery.

[36]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.